The use of liposomal anthracycline analogues for childhood malignancies: A systematic review

European Journal of Cancer

Volumn 47, Issue 13, 2011, Pages 2000-2008

  Sieswerda, E ^a   Kremer, L C M ^a   Caron, H N ^a   Van Dalen, E C ^a  

^a EMMA CHILDREN S HOSPITAL   (Netherlands)

Author keywords

Adverse drug events; Cardiotoxicity; Efficacy; Liposomal anthracyclines; Paediatric oncology; Systematic review

Indexed keywords

ANTHRACYCLINE DERIVATIVE; DAUNORUBICIN; DOXORUBICIN;

ALLERGIC REACTION; BLOOD TOXICITY; CANCER SURVIVAL; CARDIOTOXICITY; CHILDHOOD CANCER; HUMAN; INFECTION; LIPOSOMAL DELIVERY; LIVER TOXICITY; MUCOSA INFLAMMATION; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW;

ANTHRACYCLINES; CHILD; CHILD, PRESCHOOL; HUMANS; LIPOSOMES; NEOPLASMS; TREATMENT OUTCOME;

EID: 80051904456     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2011.03.024     Document Type: Article

References (32)

1. van Dalen EC, Raphael MF, Caron HN, Kremer LC. Treatment including anthracyclines versus treatment not including anthracyclines for childhood cancer. Cochrane Database Syst Rev 2009;(1):CD006647.
2. E.C. van Dalen, H.J. van der Pal, W.E. Kok, H.N. Caron, and L.C. Kremer Clinical heart failure in a cohort of children treated with anthracyclines: a long-term follow-up study Eur J Cancer 42 18 2006 3191 3198 (Pubitemid 44872945)
3. L.C. Kremer, H.J. van der Pal, M. Offringa, E.C. van Dalen, and P.A. Voute Frequency and risk factors of subclinical cardiotoxicity after anthracycline therapy in children: a systematic review Ann Oncol 13 6 2002 819 829 (Pubitemid 34752678)
4. S.E. Lipshultz, S.R. Lipsitz, and S.E. Sallan Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia J Clin Oncol 23 12 2005 2629 2636 (Pubitemid 46179451)
5. van Dalen EC, Michiels EM, Caron HN, Kremer LC. Different anthracycline derivates for reducing cardiotoxicity in cancer patients. Cochrane Database Syst Rev 2006;(4):CD005006.
6. P.G. Tardi, N.L. Boman, and P.R. Cullis Liposomal doxorubicin J Drug Target 4 3 1996 129 140 (Pubitemid 26390295)
7. E.A. Forssen, D.M. Coulter, and R.T. Proffitt Selective in vivo localization of daunorubicin small unilamellar vesicles in solid tumors Cancer Res 52 12 1992 3255 3261
8. P.K. Working, M.S. Newman, T. Sullivan, and J. Yarrington Reduction of the cardiotoxicity of doxorubicin in rabbits and dogs by encapsulation in long-circulating, pegylated liposomes J Pharmacol Exp Ther 289 2 1999 1128 1133 (Pubitemid 29191275)
9. A. Chanan-Khan, J. Szebeni, and S. Savay Complement activation following first exposure to pegylated liposomal doxorubicin (Doxil): possible role in hypersensitivity reactions Ann Oncol 14 9 2003 1430 1437 (Pubitemid 37185291)
10. M. Hackbarth, N. Haas, C. Fotopoulou, W. Lichtenegger, and J. Sehouli Chemotherapy-induced dermatological toxicity: frequencies and impact on quality of life in women's cancers. Results of a prospective study Support Care Cancer 16 3 2008 267 273 (Pubitemid 351422803)
11. G.L. Kearns, S.M. Abdel-Rahman, and S.W. Alander Developmental pharmacology-drug disposition, action, and therapy in infants and children N Engl J Med 349 12 2003 1157 1167 (Pubitemid 37122329)
12. O.S. Miettinen The need for randomization in the study of intended effects Stat Med 2 2 1983 267 271 (Pubitemid 13020139)
13. J.P. Vandenbroucke When are observational studies as credible as randomised trials? Lancet 363 9422 2004 1728 1731 (Pubitemid 38670333)
14. D.A. Grimes, and K.F. Schulz Cohort studies: marching towards outcomes Lancet 359 9303 2002 341 345 (Pubitemid 34119302)
15. A. Laupacis, G. Wells, W.S. Richardson, and P. Tugwell Users' guides to the medical literature. V. How to use an article about prognosis? Evidence-Based Medicine Working Group JAMA 272 3 1994 234 237 (Pubitemid 24209087)
16. A. Baruchel, A. Auvrignon, and Y. Perel Liposomal daunorubicin (Daunoxome (R)) for childhood acute lymphoblastic leukemia: a phase I-II study Blood 92 10 1998 234A
17. M. Clavio, C. Venturino, and I. Pierri Combination of liposomal daunorubicin (DaunoXome), fludarabine, and cytarabine (FLAD) in patients with poor-risk acute leukemia Ann Hematol 83 11 2004 696 703 (Pubitemid 39440214)
18. A. Fiorillo, G. Maggi, and N. Greco Second-line chemotherapy with the association of liposomal daunorubicin, carboplatin and etoposide in children with recurrent malignant brain tumors J Neurooncol 66 1-2 2004 179 185 (Pubitemid 38258373)
19. A. Fiorillo, G. DeRosa, and F. Giugliano Efficacy of pegylated lyposomal anthracyclines and of intra-arterial carboplatin and doxorubicin combined with local hyperthermia in a case of malignant endovascular papillary angioendothelioma Curr Drug Deliv 6 1 2009 58 61
20. H.M. Katzenstein, C. Rigsby, and P.H. Shaw Novel therapeutic approaches in the treatment of children with hepatoblastoma J Pediatr Hematol Oncol 24 9 2002 751 755 (Pubitemid 35448742)
21. R.J. Lippens Liposomal daunorubicin (DaunoXome) in children with recurrent or progressive brain tumors Pediatr Hematol Oncol 16 2 1999 131 139 (Pubitemid 29104727)
22. S. Lowis, I. Lewis, and A. Elsworth A phase I study of intravenous liposomal daunorubicin (DaunoXome) in paediatric patients with relapsed or resistant solid tumours Br J Cancer 95 5 2006 571 580 (Pubitemid 44325896)
23. N.M. Marina, D. Cochrane, and E. Harney Dose escalation and pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in children with solid tumors: a pediatric oncology group study Clin Cancer Res 8 2 2002 413 418 (Pubitemid 34193958)
24. A. Munoz, M. Maldonado, and N. Pardo Pegylated liposomal doxorubicin hydrochloride (PLD) for advanced sarcomas in children: preliminary results Pediatr Blood Cancer 43 2 2004 152 155 (Pubitemid 38891162)
25. R. Pawson, M.N. Potter, and P. Theocharous Treatment of relapse after allogeneic bone marrow transplantation with reduced intensity conditioning (FLAG ± Ida) and second allogeneic stem cell transplant Br J Haematol 115 3 2001 622 629 (Pubitemid 34015655)
26. F. Pea, D. Russo, and M. Michieli Disposition of liposomal daunorubicin during cotreatment with cytarabine in patients with leukaemia Clin Pharmacokinet 42 9 2003 851 862 (Pubitemid 36995084)
27. D. Reinhardt, G. Hempel, and G. Fleischhack Effektive Rezidivtherapie der akuten myeloischen Leukamie im Kindesalter mit liposomalem Daunorubicin und Cytarabin Klin Padiatr 214 4 2002 188 194 (Pubitemid 34925495)
28. M.S. Sedky, J.P. Vannier, and G. Leverger Liposomal daunorubicin, polyethylated glycol conjugated asparaginase (PEG-ASPA) in children with relapsed, refractory acute lymphoblastic leukemia treated on compassionate basis Haematologica 92 2007 405
29. S. Wagner, O. Peters, and C. Fels Pegylated-liposomal doxorubicin and oral topotecan in eight children with relapsed high-grade malignant brain tumors J Neurooncol 86 2 2008 175 181 (Pubitemid 350263415)
30. W. Woessmann, M. Neugebauer, R. Gossen, R. Blutters-Sawatzki, and A. Reiter Successful chemotherapy for melanotic neuroectodermal tumor of infancy in a baby Med Pediatr Oncol 40 3 2003 Mar 198 199 (Pubitemid 36110285)
31. K. Shan, A.M. Lincoff, and J.B. Young Anthracycline-induced cardiotoxicity Ann Intern Med 125 1 1996 47 58
32. Kaspers G. TRIAL Relapsed AML 2001/01: a randomised phase III study on the treatment of children and adolescents with refractory or relapsed acute myeloid leukaemia (AML). ISRCTN94206677. Available from: URL: http://www.controlled-trials.com/ISRCTN94206677.